The New Sun

Dr. Dana Flavin's motto is, "There is always a treatment, you just have to find it." She is using molecular biology and molecular pathology to find new therapies as a maverick in the use of modern day alchemy.

Her organization, The Foundation for Collaborative Medicine and Research, is a 501(3)C non profit devoted to helping people find new ways for improving their health. The foundation is is continuously developing new treatments in diseases using the most recent information and studies in medicine.

Dr. Flavin began her studies in Chemistry and Psychology in the USA, finshing her first discipline from Loyola University in Chicago. After that she attended the University of Health Sciences-Chicago Medical School for a specialty in Pharmacology, Magna cum laude.

Upon moving to Washington DC, she continued studies in Anatomy at Georgetown University and then was appointed the Science Assistant to the Associate Bureau Director for Pharmacology at FDA in Washington, D.C.

She then began another discipline in Nutrient Biochemistry after realizing that nutrients could indeed work like a pharmaceutical drug if used in the proper dosage and in the right diseases.

She was appointed the Science Advisor to the President of the Nutrition Foundation, an organization founded by the major food companies in the world, including Kraft, Hershey, Hunt and many other famous names.

After finishing a degree in Nutrition and Nutrient Biochemistry at Howard University in Washington, D.C. she moved to Germany and commenced studies in Medicine with a specialty in Biochemical Pharmacology with a degree in Medicine from Leopold Franzens Unversity at the University of Innsbruck Austria. Her training is in Internal Medicine and Oncology from Germany and Austria.

In 2005 she returned to the USA to set up The Foundation for Collaborative Medicine and Research in Greenwich, Ct. where she has been developing new therapies that are natural as well as finding and assisitng colleagues all over the world with immunotherapy and monoclonal antibody therapy.